NASDAQ · Medical - Devices

BJDX (BJDX) Stock

$1.10 +6.80% NASDAQ: BJDX Healthcare

Valuation

MetricValue
Price$1.10
Market Cap$498895
P/E Ratio-0.32
P/B Ratio1.20
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$16.68
52-Week Low$1.03
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-171.56%
ROA-79.65%
ROCE-116.67%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio5.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-3.0M$-9.0M$-10.0M$-7.0M$-7.0M
Net Profit$-4.0M$-9.0M$-10.0M$-8.0M$-7.0M
EPS$-118.68$-292.88$-290.48$-456.76$-15.25
Op Margin—-3741.5%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$21.0M$14.0M$5.0M$7.0M$7.0M
Total Liabilities$1.0M$2.0M$2.0M$1.0M$1.0M
Cash$19.0M$10.0M$2.0M$4.0M$5.0M
Borrowings$0$0$0$0$0

Latest News

Bluejay Diagnostics Completes Enrollment in SYMON-II Clinical Validation Study MT Newswires · Jul 21, 2026 Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study GlobeNewswire · Jul 21, 2026 BC-Most Active Stocks Associated Press · Jul 7, 2026 Top Premarket Gainers MT Newswires · Jul 7, 2026 Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules GlobeNewswire · Jun 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-4.0M$-8.0M$-8.0M$-8.0M$-6.0M
Investing Cash Flow$0$-2.0M$-1.0M$-1.0M$0
Financing Cash Flow$-1.0M$0$1.0M$-2.0M$-1.0M
Net Cash Flow$18.0M$-9.0M$-8.0M$2.0M$1.0M
Free Cash Flow$-4.0M$-9.0M$-9.0M$-8.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-0.22
FCF Yield-300.49%
Quick Ratio2.81
Interest Coverage—
Return 1Y-79.42%
Return 3Y-99.98%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCTXZBriaCell Therapeutics Corp. Warrant $0.10 +8.47% -0.30 $188186 0.00%
ELAB $0.92 +2.21% 0.00 $1.78M 0.00%
MLECMoolec Science S.A. $7.37 +2.43% -0.03 $5.35M 0.00%
MSPRMSP Recovery, Inc. $0.01 +66.67% 0.00 $137744 0.00%
NKGNNKGen Biotech, Inc. $0.06 +0.00% -0.04 $7.84M 0.00%

About BJDX

BJDX is led by CEO Indranil Dey, employs 7 people, headquartered in US, publicly traded since 2021.

BJDX stock trades at $1.10 with a market capitalization of $498895. The stock is valued at a price-to-earnings (P/E) ratio of -0.32, price-to-book of 1.20, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.03 and $16.68, and currently trades 93.4% below its 52-week high.

On profitability, BJDX generates a return on equity (ROE) of -171.56%, return on capital employed of -116.67%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides